PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy Article Swipe
Sylvain Simon
,
Valentin Voillet
,
Virginie Vignard
,
Zhong Wu
,
Camille Dabrowski
,
Nicolas Jouand
,
Tiffany Beauvais
,
Amir Khammari
,
Cécile Braudeau
,
Régis Josien
,
Olivier Adotévi
,
Caroline Laheurte
,
F. Aubin
,
C. Nardin
,
Samuel Rulli
,
Raphaël Gottardo
,
Nirasha Ramchurren
,
Martin A. Cheever
,
Steven P. Fling
,
Candice D. Church
,
Paul Nghiem
,
Brigitte Dréno
,
Stanley R. Riddell
,
Nathalie Labarrière
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1136/jitc-2020-001631
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1136/jitc-2020-001631
Background Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated. Methods We isolated peripheral blood mononuclear cell from three independent cohorts of melanoma and Merkel cell carcinoma patients treated with PD-1 inhibitor, at baseline and longitudinally after therapy. Using multiparameter flow cytometry and cell sorting, we isolated four subsets of CD8 + T cells, based on PD-1 and TIGIT expression profiles. We performed phenotypic characterization, T cell receptor sequencing, targeted transcriptomic analysis and antitumor reactivity assays to thoroughly characterize each of these subsets. Results We documented that the frequency of circulating PD-1 + TIGIT + (DPOS) CD8 + T-cells after 1 month of anti-PD-1 therapy was associated with clinical response and overall survival. This DPOS T-cell population was enriched in highly activated T-cells, tumor-specific and emerging T-cell clonotypes and T lymphocytes overexpressing CXCR5, a key marker of the CD8 cytotoxic follicular T cell population. Additionally, transcriptomic profiling defined a specific gene signature for this population as well as the overexpression of specific pathways associated with the therapeutic response. Conclusions Our results provide a convincing rationale for monitoring this PD-1 + TIGIT + circulating population as an early cellular-based marker of therapeutic response to anti-PD-1 therapy.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1136/jitc-2020-001631
- https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdf
- OA Status
- gold
- Cited By
- 65
- References
- 86
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3102804765
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3102804765Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1136/jitc-2020-001631Digital Object Identifier
- Title
-
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-11-01Full publication date if available
- Authors
-
Sylvain Simon, Valentin Voillet, Virginie Vignard, Zhong Wu, Camille Dabrowski, Nicolas Jouand, Tiffany Beauvais, Amir Khammari, Cécile Braudeau, Régis Josien, Olivier Adotévi, Caroline Laheurte, F. Aubin, C. Nardin, Samuel Rulli, Raphaël Gottardo, Nirasha Ramchurren, Martin A. Cheever, Steven P. Fling, Candice D. Church, Paul Nghiem, Brigitte Dréno, Stanley R. Riddell, Nathalie LabarrièreList of authors in order
- Landing page
-
https://doi.org/10.1136/jitc-2020-001631Publisher landing page
- PDF URL
-
https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdfDirect OA link when available
- Concepts
-
TIGIT, CD8, Cytotoxic T cell, Population, Immunology, T cell, Medicine, Cancer research, Immune system, Immunotherapy, Flow cytometry, Biology, In vitro, Environmental health, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
65Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 9, 2024: 16, 2023: 17, 2022: 13, 2021: 10Per-year citation counts (last 5 years)
- References (count)
-
86Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3102804765 |
|---|---|
| doi | https://doi.org/10.1136/jitc-2020-001631 |
| ids.doi | https://doi.org/10.1136/jitc-2020-001631 |
| ids.mag | 3102804765 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33188038 |
| ids.openalex | https://openalex.org/W3102804765 |
| fwci | 4.0235114 |
| mesh[0].qualifier_ui | Q000276 |
| mesh[0].descriptor_ui | D018414 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | immunology |
| mesh[0].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[1].qualifier_ui | Q000378 |
| mesh[1].descriptor_ui | D018414 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | metabolism |
| mesh[1].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[2].qualifier_ui | Q000097 |
| mesh[2].descriptor_ui | D015266 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | blood |
| mesh[2].descriptor_name | Carcinoma, Merkel Cell |
| mesh[3].qualifier_ui | Q000188 |
| mesh[3].descriptor_ui | D015266 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | drug therapy |
| mesh[3].descriptor_name | Carcinoma, Merkel Cell |
| mesh[4].qualifier_ui | Q000276 |
| mesh[4].descriptor_ui | D015266 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | immunology |
| mesh[4].descriptor_name | Carcinoma, Merkel Cell |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D006801 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Humans |
| mesh[6].qualifier_ui | Q000494 |
| mesh[6].descriptor_ui | D000082082 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | pharmacology |
| mesh[6].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[7].qualifier_ui | Q000097 |
| mesh[7].descriptor_ui | D008545 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | blood |
| mesh[7].descriptor_name | Melanoma |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D008545 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Melanoma |
| mesh[9].qualifier_ui | Q000276 |
| mesh[9].descriptor_ui | D008545 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | immunology |
| mesh[9].descriptor_name | Melanoma |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D011237 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Predictive Value of Tests |
| mesh[11].qualifier_ui | Q000037 |
| mesh[11].descriptor_ui | D061026 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | antagonists & inhibitors |
| mesh[11].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[12].qualifier_ui | Q000096 |
| mesh[12].descriptor_ui | D061026 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | biosynthesis |
| mesh[12].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[13].qualifier_ui | Q000097 |
| mesh[13].descriptor_ui | D061026 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | blood |
| mesh[13].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[14].qualifier_ui | Q000276 |
| mesh[14].descriptor_ui | D061026 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | immunology |
| mesh[14].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[15].qualifier_ui | Q000276 |
| mesh[15].descriptor_ui | D054380 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | immunology |
| mesh[15].descriptor_name | Receptors, CXCR5 |
| mesh[16].qualifier_ui | Q000096 |
| mesh[16].descriptor_ui | D011971 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | biosynthesis |
| mesh[16].descriptor_name | Receptors, Immunologic |
| mesh[17].qualifier_ui | Q000097 |
| mesh[17].descriptor_ui | D011971 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | blood |
| mesh[17].descriptor_name | Receptors, Immunologic |
| mesh[18].qualifier_ui | Q000276 |
| mesh[18].descriptor_ui | D011971 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | immunology |
| mesh[18].descriptor_name | Receptors, Immunologic |
| mesh[19].qualifier_ui | Q000276 |
| mesh[19].descriptor_ui | D016176 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | immunology |
| mesh[19].descriptor_name | T-Lymphocyte Subsets |
| mesh[20].qualifier_ui | Q000276 |
| mesh[20].descriptor_ui | D018414 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | immunology |
| mesh[20].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[21].qualifier_ui | Q000378 |
| mesh[21].descriptor_ui | D018414 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | metabolism |
| mesh[21].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[22].qualifier_ui | Q000097 |
| mesh[22].descriptor_ui | D015266 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | blood |
| mesh[22].descriptor_name | Carcinoma, Merkel Cell |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D015266 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Carcinoma, Merkel Cell |
| mesh[24].qualifier_ui | Q000276 |
| mesh[24].descriptor_ui | D015266 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | immunology |
| mesh[24].descriptor_name | Carcinoma, Merkel Cell |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D006801 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Humans |
| mesh[26].qualifier_ui | Q000494 |
| mesh[26].descriptor_ui | D000082082 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | pharmacology |
| mesh[26].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[27].qualifier_ui | Q000097 |
| mesh[27].descriptor_ui | D008545 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | blood |
| mesh[27].descriptor_name | Melanoma |
| mesh[28].qualifier_ui | Q000188 |
| mesh[28].descriptor_ui | D008545 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | drug therapy |
| mesh[28].descriptor_name | Melanoma |
| mesh[29].qualifier_ui | Q000276 |
| mesh[29].descriptor_ui | D008545 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | immunology |
| mesh[29].descriptor_name | Melanoma |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D011237 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Predictive Value of Tests |
| mesh[31].qualifier_ui | Q000037 |
| mesh[31].descriptor_ui | D061026 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | antagonists & inhibitors |
| mesh[31].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[32].qualifier_ui | Q000096 |
| mesh[32].descriptor_ui | D061026 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | biosynthesis |
| mesh[32].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[33].qualifier_ui | Q000097 |
| mesh[33].descriptor_ui | D061026 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | blood |
| mesh[33].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[34].qualifier_ui | Q000276 |
| mesh[34].descriptor_ui | D061026 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | immunology |
| mesh[34].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[35].qualifier_ui | Q000276 |
| mesh[35].descriptor_ui | D054380 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | immunology |
| mesh[35].descriptor_name | Receptors, CXCR5 |
| mesh[36].qualifier_ui | Q000096 |
| mesh[36].descriptor_ui | D011971 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | biosynthesis |
| mesh[36].descriptor_name | Receptors, Immunologic |
| mesh[37].qualifier_ui | Q000097 |
| mesh[37].descriptor_ui | D011971 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | blood |
| mesh[37].descriptor_name | Receptors, Immunologic |
| mesh[38].qualifier_ui | Q000276 |
| mesh[38].descriptor_ui | D011971 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | immunology |
| mesh[38].descriptor_name | Receptors, Immunologic |
| mesh[39].qualifier_ui | Q000276 |
| mesh[39].descriptor_ui | D016176 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | immunology |
| mesh[39].descriptor_name | T-Lymphocyte Subsets |
| mesh[40].qualifier_ui | Q000276 |
| mesh[40].descriptor_ui | D018414 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | immunology |
| mesh[40].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[41].qualifier_ui | Q000378 |
| mesh[41].descriptor_ui | D018414 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | metabolism |
| mesh[41].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[42].qualifier_ui | Q000097 |
| mesh[42].descriptor_ui | D015266 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | blood |
| mesh[42].descriptor_name | Carcinoma, Merkel Cell |
| mesh[43].qualifier_ui | Q000188 |
| mesh[43].descriptor_ui | D015266 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | drug therapy |
| mesh[43].descriptor_name | Carcinoma, Merkel Cell |
| mesh[44].qualifier_ui | Q000276 |
| mesh[44].descriptor_ui | D015266 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | immunology |
| mesh[44].descriptor_name | Carcinoma, Merkel Cell |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D006801 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Humans |
| mesh[46].qualifier_ui | Q000494 |
| mesh[46].descriptor_ui | D000082082 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | pharmacology |
| mesh[46].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[47].qualifier_ui | Q000097 |
| mesh[47].descriptor_ui | D008545 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | blood |
| mesh[47].descriptor_name | Melanoma |
| mesh[48].qualifier_ui | Q000188 |
| mesh[48].descriptor_ui | D008545 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | drug therapy |
| mesh[48].descriptor_name | Melanoma |
| mesh[49].qualifier_ui | Q000276 |
| mesh[49].descriptor_ui | D008545 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | immunology |
| mesh[49].descriptor_name | Melanoma |
| type | article |
| title | PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy |
| biblio.issue | 2 |
| biblio.volume | 8 |
| biblio.last_page | e001631 |
| biblio.first_page | e001631 |
| grants[0].funder | https://openalex.org/F4320322363 |
| grants[0].award_id | |
| grants[0].funder_display_name | Ligue Contre le Cancer |
| topics[0].id | https://openalex.org/T11491 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | CAR-T cell therapy research |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9968000054359436 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T10580 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9930999875068665 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immunotherapy and Immune Responses |
| funders[0].id | https://openalex.org/F4320322363 |
| funders[0].ror | https://ror.org/00rkrv905 |
| funders[0].display_name | Ligue Contre le Cancer |
| is_xpac | False |
| apc_list.value | 2600 |
| apc_list.currency | USD |
| apc_list.value_usd | 2600 |
| apc_paid.value | 2600 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2600 |
| concepts[0].id | https://openalex.org/C2779118045 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9404107928276062 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q21114021 |
| concepts[0].display_name | TIGIT |
| concepts[1].id | https://openalex.org/C167672396 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6278972625732422 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[1].display_name | CD8 |
| concepts[2].id | https://openalex.org/C154317977 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6178950071334839 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q376266 |
| concepts[2].display_name | Cytotoxic T cell |
| concepts[3].id | https://openalex.org/C2908647359 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5856128931045532 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[3].display_name | Population |
| concepts[4].id | https://openalex.org/C203014093 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5443959832191467 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[4].display_name | Immunology |
| concepts[5].id | https://openalex.org/C2776090121 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5183435678482056 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q193529 |
| concepts[5].display_name | T cell |
| concepts[6].id | https://openalex.org/C71924100 |
| concepts[6].level | 0 |
| concepts[6].score | 0.49760153889656067 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[6].display_name | Medicine |
| concepts[7].id | https://openalex.org/C502942594 |
| concepts[7].level | 1 |
| concepts[7].score | 0.46187710762023926 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[7].display_name | Cancer research |
| concepts[8].id | https://openalex.org/C8891405 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4359568655490875 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[8].display_name | Immune system |
| concepts[9].id | https://openalex.org/C2777701055 |
| concepts[9].level | 3 |
| concepts[9].score | 0.42709171772003174 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[9].display_name | Immunotherapy |
| concepts[10].id | https://openalex.org/C553184892 |
| concepts[10].level | 2 |
| concepts[10].score | 0.41401198506355286 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1141429 |
| concepts[10].display_name | Flow cytometry |
| concepts[11].id | https://openalex.org/C86803240 |
| concepts[11].level | 0 |
| concepts[11].score | 0.3432544469833374 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[11].display_name | Biology |
| concepts[12].id | https://openalex.org/C202751555 |
| concepts[12].level | 2 |
| concepts[12].score | 0.07320705056190491 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[12].display_name | In vitro |
| concepts[13].id | https://openalex.org/C99454951 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[13].display_name | Environmental health |
| concepts[14].id | https://openalex.org/C55493867 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[14].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/tigit |
| keywords[0].score | 0.9404107928276062 |
| keywords[0].display_name | TIGIT |
| keywords[1].id | https://openalex.org/keywords/cd8 |
| keywords[1].score | 0.6278972625732422 |
| keywords[1].display_name | CD8 |
| keywords[2].id | https://openalex.org/keywords/cytotoxic-t-cell |
| keywords[2].score | 0.6178950071334839 |
| keywords[2].display_name | Cytotoxic T cell |
| keywords[3].id | https://openalex.org/keywords/population |
| keywords[3].score | 0.5856128931045532 |
| keywords[3].display_name | Population |
| keywords[4].id | https://openalex.org/keywords/immunology |
| keywords[4].score | 0.5443959832191467 |
| keywords[4].display_name | Immunology |
| keywords[5].id | https://openalex.org/keywords/t-cell |
| keywords[5].score | 0.5183435678482056 |
| keywords[5].display_name | T cell |
| keywords[6].id | https://openalex.org/keywords/medicine |
| keywords[6].score | 0.49760153889656067 |
| keywords[6].display_name | Medicine |
| keywords[7].id | https://openalex.org/keywords/cancer-research |
| keywords[7].score | 0.46187710762023926 |
| keywords[7].display_name | Cancer research |
| keywords[8].id | https://openalex.org/keywords/immune-system |
| keywords[8].score | 0.4359568655490875 |
| keywords[8].display_name | Immune system |
| keywords[9].id | https://openalex.org/keywords/immunotherapy |
| keywords[9].score | 0.42709171772003174 |
| keywords[9].display_name | Immunotherapy |
| keywords[10].id | https://openalex.org/keywords/flow-cytometry |
| keywords[10].score | 0.41401198506355286 |
| keywords[10].display_name | Flow cytometry |
| keywords[11].id | https://openalex.org/keywords/biology |
| keywords[11].score | 0.3432544469833374 |
| keywords[11].display_name | Biology |
| keywords[12].id | https://openalex.org/keywords/in-vitro |
| keywords[12].score | 0.07320705056190491 |
| keywords[12].display_name | In vitro |
| language | en |
| locations[0].id | doi:10.1136/jitc-2020-001631 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2754803477 |
| locations[0].source.issn | 2051-1426 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2051-1426 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Journal for ImmunoTherapy of Cancer |
| locations[0].source.host_organization | https://openalex.org/P4310319945 |
| locations[0].source.host_organization_name | BMJ |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319945 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal for ImmunoTherapy of Cancer |
| locations[0].landing_page_url | https://doi.org/10.1136/jitc-2020-001631 |
| locations[1].id | pmid:33188038 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal for immunotherapy of cancer |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33188038 |
| locations[2].id | pmh:oai:HAL:inserm-03011429v1 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306402512 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| locations[2].source.host_organization | https://openalex.org/I1294671590 |
| locations[2].source.host_organization_name | Centre National de la Recherche Scientifique |
| locations[2].source.host_organization_lineage | https://openalex.org/I1294671590 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Journal articles |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Journal for Immunotherapy of Cancer, 2020, 8, pp.e001631. ⟨10.1136/jitc-2020-001631⟩ |
| locations[2].landing_page_url | https://inserm.hal.science/inserm-03011429 |
| locations[3].id | pmh:oai:doaj.org/article:e9c7452d81254d408bd2276450f26642 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | cc-by-sa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020) |
| locations[3].landing_page_url | https://doaj.org/article/e9c7452d81254d408bd2276450f26642 |
| locations[4].id | pmh:oai:pubmedcentral.nih.gov:7668369 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S2764455111 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | PubMed Central |
| locations[4].source.host_organization | https://openalex.org/I1299303238 |
| locations[4].source.host_organization_name | National Institutes of Health |
| locations[4].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[4].license | |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | J Immunother Cancer |
| locations[4].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7668369 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5006738419 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5985-3946 |
| authorships[0].author.display_name | Sylvain Simon |
| authorships[0].countries | FR, US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[0].affiliations[0].raw_affiliation_string | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I154526488 |
| authorships[0].affiliations[1].raw_affiliation_string | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[0].affiliations[2].raw_affiliation_string | LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[0].institutions[0].id | https://openalex.org/I154526488 |
| authorships[0].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[0].institutions[0].type | government |
| authorships[0].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Inserm |
| authorships[0].institutions[1].id | https://openalex.org/I4210089486 |
| authorships[0].institutions[1].ror | https://ror.org/007ps6h72 |
| authorships[0].institutions[1].type | nonprofit |
| authorships[0].institutions[1].lineage | https://openalex.org/I4210089486 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Fred Hutch Cancer Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Sylvain Simon |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France, LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[1].author.id | https://openalex.org/A5030920948 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5751-3881 |
| authorships[1].author.display_name | Valentin Voillet |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[1].affiliations[0].raw_affiliation_string | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[1].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[1].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Valentin Voillet |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[2].author.id | https://openalex.org/A5033376651 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6702-2824 |
| authorships[2].author.display_name | Virginie Vignard |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].raw_affiliation_string | LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I154526488 |
| authorships[2].affiliations[1].raw_affiliation_string | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[2].affiliations[2].institution_ids | https://openalex.org/I3019204325 |
| authorships[2].affiliations[2].raw_affiliation_string | CHU of Nantes, Nantes, France |
| authorships[2].institutions[0].id | https://openalex.org/I3019204325 |
| authorships[2].institutions[0].ror | https://ror.org/05c1qsg97 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I3019204325 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Centre Hospitalier Universitaire de Nantes |
| authorships[2].institutions[1].id | https://openalex.org/I154526488 |
| authorships[2].institutions[1].ror | https://ror.org/02vjkv261 |
| authorships[2].institutions[1].type | government |
| authorships[2].institutions[1].lineage | https://openalex.org/I154526488 |
| authorships[2].institutions[1].country_code | FR |
| authorships[2].institutions[1].display_name | Inserm |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Virginie Vignard |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | CHU of Nantes, Nantes, France, Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France, LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[3].author.id | https://openalex.org/A5031819351 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5103-9517 |
| authorships[3].author.display_name | Zhong Wu |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210146214 |
| authorships[3].affiliations[0].raw_affiliation_string | Qiagen Sciences, Frederick, Maryland, USA |
| authorships[3].institutions[0].id | https://openalex.org/I4210146214 |
| authorships[3].institutions[0].ror | https://ror.org/04s4jww20 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210122143, https://openalex.org/I4210146214 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Qiagen (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Zhong Wu |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Qiagen Sciences, Frederick, Maryland, USA |
| authorships[4].author.id | https://openalex.org/A5090091380 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Camille Dabrowski |
| authorships[4].affiliations[0].raw_affiliation_string | Dermatology Unit, CHU Nantes, Nantes, France |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Camille Dabrowski |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Dermatology Unit, CHU Nantes, Nantes, France |
| authorships[5].author.id | https://openalex.org/A5082674992 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-4967-5909 |
| authorships[5].author.display_name | Nicolas Jouand |
| authorships[5].affiliations[0].raw_affiliation_string | LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I4400009061 |
| authorships[5].affiliations[1].raw_affiliation_string | Platform Cytocell, SFR Santé Francois Bonamy, Nantes, France |
| authorships[5].institutions[0].id | https://openalex.org/I4400009061 |
| authorships[5].institutions[0].ror | https://ror.org/03p6ach34 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I154526488, https://openalex.org/I4392021198, https://openalex.org/I4400009061, https://openalex.org/I97188460, https://openalex.org/I97188460 |
| authorships[5].institutions[0].country_code | |
| authorships[5].institutions[0].display_name | Structure Fédérative de Recherche Bonamy |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Nicolas Jouand |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France, Platform Cytocell, SFR Santé Francois Bonamy, Nantes, France |
| authorships[6].author.id | https://openalex.org/A5056568250 |
| authorships[6].author.orcid | https://orcid.org/0009-0005-3065-3381 |
| authorships[6].author.display_name | Tiffany Beauvais |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I3019204325 |
| authorships[6].affiliations[0].raw_affiliation_string | CHU of Nantes, Nantes, France |
| authorships[6].affiliations[1].raw_affiliation_string | LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[6].affiliations[2].institution_ids | https://openalex.org/I154526488 |
| authorships[6].affiliations[2].raw_affiliation_string | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[6].institutions[0].id | https://openalex.org/I3019204325 |
| authorships[6].institutions[0].ror | https://ror.org/05c1qsg97 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I3019204325 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Centre Hospitalier Universitaire de Nantes |
| authorships[6].institutions[1].id | https://openalex.org/I154526488 |
| authorships[6].institutions[1].ror | https://ror.org/02vjkv261 |
| authorships[6].institutions[1].type | government |
| authorships[6].institutions[1].lineage | https://openalex.org/I154526488 |
| authorships[6].institutions[1].country_code | FR |
| authorships[6].institutions[1].display_name | Inserm |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Tiffany Beauvais |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | CHU of Nantes, Nantes, France, Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France, LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[7].author.id | https://openalex.org/A5001247907 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-9328-8004 |
| authorships[7].author.display_name | Amir Khammari |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I154526488 |
| authorships[7].affiliations[0].raw_affiliation_string | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[7].affiliations[1].raw_affiliation_string | Dermatology Unit, CHU Nantes, Nantes, France |
| authorships[7].institutions[0].id | https://openalex.org/I154526488 |
| authorships[7].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[7].institutions[0].type | government |
| authorships[7].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Inserm |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Amir Khammari |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Dermatology Unit, CHU Nantes, Nantes, France, Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[8].author.id | https://openalex.org/A5061969978 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-6661-8047 |
| authorships[8].author.display_name | Cécile Braudeau |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].raw_affiliation_string | CHU Nantes, Laboratoire d'Immunologie, Nantes, France |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I154526488, https://openalex.org/I97188460 |
| authorships[8].affiliations[1].raw_affiliation_string | CRTI, INSERM, Université de Nantes, Nantes, France |
| authorships[8].institutions[0].id | https://openalex.org/I154526488 |
| authorships[8].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[8].institutions[0].type | government |
| authorships[8].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Inserm |
| authorships[8].institutions[1].id | https://openalex.org/I97188460 |
| authorships[8].institutions[1].ror | https://ror.org/03gnr7b55 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I97188460 |
| authorships[8].institutions[1].country_code | FR |
| authorships[8].institutions[1].display_name | Nantes Université |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Cécile Braudeau |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | CHU Nantes, Laboratoire d'Immunologie, Nantes, France, CRTI, INSERM, Université de Nantes, Nantes, France |
| authorships[9].author.id | https://openalex.org/A5015103954 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-7900-7413 |
| authorships[9].author.display_name | Régis Josien |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I97188460 |
| authorships[9].affiliations[0].raw_affiliation_string | CRTI, INSERM, Université de Nantes, Nantes, France |
| authorships[9].institutions[0].id | https://openalex.org/I154526488 |
| authorships[9].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[9].institutions[0].type | government |
| authorships[9].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Inserm |
| authorships[9].institutions[1].id | https://openalex.org/I97188460 |
| authorships[9].institutions[1].ror | https://ror.org/03gnr7b55 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I97188460 |
| authorships[9].institutions[1].country_code | FR |
| authorships[9].institutions[1].display_name | Nantes Université |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Régis Josien |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | CRTI, INSERM, Université de Nantes, Nantes, France |
| authorships[10].author.id | https://openalex.org/A5060518732 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-7742-136X |
| authorships[10].author.display_name | Olivier Adotévi |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4409125604, https://openalex.org/I4409125604, https://openalex.org/I4407990293, https://openalex.org/I4407990293, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I4407990293, https://openalex.org/I4407990293, https://openalex.org/I4407990293 |
| authorships[10].affiliations[0].raw_affiliation_string | INSERM UMR 1098, Besançon, France |
| authorships[10].affiliations[1].institution_ids | https://openalex.org/I4210087978, https://openalex.org/I4210087978, https://openalex.org/I4407990293, https://openalex.org/I4407990293 |
| authorships[10].affiliations[1].raw_affiliation_string | CHU de BESANCON, Besancon, France |
| authorships[10].institutions[0].id | https://openalex.org/I4409125604 |
| authorships[10].institutions[0].ror | https://ror.org/05w3vvc59 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I154526488, https://openalex.org/I4210128919, https://openalex.org/I4407990293, https://openalex.org/I4409125604 |
| authorships[10].institutions[0].country_code | |
| authorships[10].institutions[0].display_name | Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique |
| authorships[10].institutions[1].id | https://openalex.org/I4407990293 |
| authorships[10].institutions[1].ror | https://ror.org/04asdee31 |
| authorships[10].institutions[1].type | education |
| authorships[10].institutions[1].lineage | https://openalex.org/I4407990293 |
| authorships[10].institutions[1].country_code | |
| authorships[10].institutions[1].display_name | Université Marie et Louis Pasteur |
| authorships[10].institutions[2].id | https://openalex.org/I4210087978 |
| authorships[10].institutions[2].ror | https://ror.org/0084te143 |
| authorships[10].institutions[2].type | healthcare |
| authorships[10].institutions[2].lineage | https://openalex.org/I4210087978 |
| authorships[10].institutions[2].country_code | FR |
| authorships[10].institutions[2].display_name | Centre Hospitalier Universitaire de Besançon |
| authorships[10].institutions[3].id | https://openalex.org/I154526488 |
| authorships[10].institutions[3].ror | https://ror.org/02vjkv261 |
| authorships[10].institutions[3].type | government |
| authorships[10].institutions[3].lineage | https://openalex.org/I154526488 |
| authorships[10].institutions[3].country_code | FR |
| authorships[10].institutions[3].display_name | Inserm |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Olivier Adotevi |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | CHU de BESANCON, Besancon, France, INSERM UMR 1098, Besançon, France |
| authorships[11].author.id | https://openalex.org/A5019366639 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-1364-4556 |
| authorships[11].author.display_name | Caroline Laheurte |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210087978, https://openalex.org/I4210087978, https://openalex.org/I4407990293, https://openalex.org/I4407990293 |
| authorships[11].affiliations[0].raw_affiliation_string | CHU de BESANCON, Besancon, France |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I4409125604, https://openalex.org/I4409125604, https://openalex.org/I4407990293, https://openalex.org/I4407990293, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I154526488, https://openalex.org/I4407990293, https://openalex.org/I4407990293, https://openalex.org/I4407990293 |
| authorships[11].affiliations[1].raw_affiliation_string | INSERM UMR 1098, Besançon, France |
| authorships[11].institutions[0].id | https://openalex.org/I4409125604 |
| authorships[11].institutions[0].ror | https://ror.org/05w3vvc59 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I154526488, https://openalex.org/I4210128919, https://openalex.org/I4407990293, https://openalex.org/I4409125604 |
| authorships[11].institutions[0].country_code | |
| authorships[11].institutions[0].display_name | Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique |
| authorships[11].institutions[1].id | https://openalex.org/I4407990293 |
| authorships[11].institutions[1].ror | https://ror.org/04asdee31 |
| authorships[11].institutions[1].type | education |
| authorships[11].institutions[1].lineage | https://openalex.org/I4407990293 |
| authorships[11].institutions[1].country_code | |
| authorships[11].institutions[1].display_name | Université Marie et Louis Pasteur |
| authorships[11].institutions[2].id | https://openalex.org/I4210087978 |
| authorships[11].institutions[2].ror | https://ror.org/0084te143 |
| authorships[11].institutions[2].type | healthcare |
| authorships[11].institutions[2].lineage | https://openalex.org/I4210087978 |
| authorships[11].institutions[2].country_code | FR |
| authorships[11].institutions[2].display_name | Centre Hospitalier Universitaire de Besançon |
| authorships[11].institutions[3].id | https://openalex.org/I154526488 |
| authorships[11].institutions[3].ror | https://ror.org/02vjkv261 |
| authorships[11].institutions[3].type | government |
| authorships[11].institutions[3].lineage | https://openalex.org/I154526488 |
| authorships[11].institutions[3].country_code | FR |
| authorships[11].institutions[3].display_name | Inserm |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Caroline Laheurte |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | CHU de BESANCON, Besancon, France, INSERM UMR 1098, Besançon, France |
| authorships[12].author.id | https://openalex.org/A5044024585 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-1421-4996 |
| authorships[12].author.display_name | F. Aubin |
| authorships[12].countries | FR |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210087978 |
| authorships[12].affiliations[0].raw_affiliation_string | Dermatology Unit, Besancon Hospital, Besançon, France |
| authorships[12].institutions[0].id | https://openalex.org/I4210087978 |
| authorships[12].institutions[0].ror | https://ror.org/0084te143 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210087978 |
| authorships[12].institutions[0].country_code | FR |
| authorships[12].institutions[0].display_name | Centre Hospitalier Universitaire de Besançon |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | François Aubin |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Dermatology Unit, Besancon Hospital, Besançon, France |
| authorships[13].author.id | https://openalex.org/A5065434876 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | C. Nardin |
| authorships[13].countries | FR |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210087978 |
| authorships[13].affiliations[0].raw_affiliation_string | Dermatology Unit, Besancon Hospital, Besançon, France |
| authorships[13].institutions[0].id | https://openalex.org/I4210087978 |
| authorships[13].institutions[0].ror | https://ror.org/0084te143 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210087978 |
| authorships[13].institutions[0].country_code | FR |
| authorships[13].institutions[0].display_name | Centre Hospitalier Universitaire de Besançon |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Charles Nardin |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Dermatology Unit, Besancon Hospital, Besançon, France |
| authorships[14].author.id | https://openalex.org/A5061572362 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Samuel Rulli |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210146214 |
| authorships[14].affiliations[0].raw_affiliation_string | Qiagen Sciences, Frederick, Maryland, USA |
| authorships[14].institutions[0].id | https://openalex.org/I4210146214 |
| authorships[14].institutions[0].ror | https://ror.org/04s4jww20 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210122143, https://openalex.org/I4210146214 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Qiagen (United States) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Samuel Rulli |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Qiagen Sciences, Frederick, Maryland, USA |
| authorships[15].author.id | https://openalex.org/A5005741024 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-3867-0232 |
| authorships[15].author.display_name | Raphaël Gottardo |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[15].affiliations[0].raw_affiliation_string | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[15].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[15].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[15].institutions[0].type | nonprofit |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Raphael Gottardo |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[16].author.id | https://openalex.org/A5017244881 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-6613-9342 |
| authorships[16].author.display_name | Nirasha Ramchurren |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[16].affiliations[0].raw_affiliation_string | Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[16].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[16].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[16].institutions[0].type | nonprofit |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Nirasha Ramchurren |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[17].author.id | https://openalex.org/A5007551071 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-6892-4141 |
| authorships[17].author.display_name | Martin A. Cheever |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[17].affiliations[0].raw_affiliation_string | Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[17].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[17].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[17].institutions[0].type | nonprofit |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Martin Cheever |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[18].author.id | https://openalex.org/A5023766816 |
| authorships[18].author.orcid | https://orcid.org/0000-0001-6263-0153 |
| authorships[18].author.display_name | Steven P. Fling |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[18].affiliations[0].raw_affiliation_string | Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[18].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[18].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[18].institutions[0].type | nonprofit |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Steven P Fling |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[19].author.id | https://openalex.org/A5015132177 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-1582-8292 |
| authorships[19].author.display_name | Candice D. Church |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I201448701 |
| authorships[19].affiliations[0].raw_affiliation_string | Dermatology, Division of Dermatology, Department of Medicine, UW School of Medicine, Seattle, Washington, USA |
| authorships[19].institutions[0].id | https://openalex.org/I201448701 |
| authorships[19].institutions[0].ror | https://ror.org/00cvxb145 |
| authorships[19].institutions[0].type | education |
| authorships[19].institutions[0].lineage | https://openalex.org/I201448701 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | University of Washington |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Candice D Church |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Dermatology, Division of Dermatology, Department of Medicine, UW School of Medicine, Seattle, Washington, USA |
| authorships[20].author.id | https://openalex.org/A5082643048 |
| authorships[20].author.orcid | https://orcid.org/0000-0003-2784-963X |
| authorships[20].author.display_name | Paul Nghiem |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I201448701 |
| authorships[20].affiliations[0].raw_affiliation_string | Dermatology, Division of Dermatology, Department of Medicine, UW School of Medicine, Seattle, Washington, USA |
| authorships[20].institutions[0].id | https://openalex.org/I201448701 |
| authorships[20].institutions[0].ror | https://ror.org/00cvxb145 |
| authorships[20].institutions[0].type | education |
| authorships[20].institutions[0].lineage | https://openalex.org/I201448701 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | University of Washington |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Paul Nghiem |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Dermatology, Division of Dermatology, Department of Medicine, UW School of Medicine, Seattle, Washington, USA |
| authorships[21].author.id | https://openalex.org/A5002644565 |
| authorships[21].author.orcid | https://orcid.org/0000-0001-5574-5825 |
| authorships[21].author.display_name | Brigitte Dréno |
| authorships[21].countries | FR |
| authorships[21].affiliations[0].raw_affiliation_string | Dermatology Unit, CHU Nantes, Nantes, France |
| authorships[21].affiliations[1].institution_ids | https://openalex.org/I154526488 |
| authorships[21].affiliations[1].raw_affiliation_string | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[21].institutions[0].id | https://openalex.org/I154526488 |
| authorships[21].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[21].institutions[0].type | government |
| authorships[21].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[21].institutions[0].country_code | FR |
| authorships[21].institutions[0].display_name | Inserm |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Brigitte Dreno |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Dermatology Unit, CHU Nantes, Nantes, France, Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[22].author.id | https://openalex.org/A5087281332 |
| authorships[22].author.orcid | https://orcid.org/0000-0002-4688-9920 |
| authorships[22].author.display_name | Stanley R. Riddell |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4210089486 |
| authorships[22].affiliations[0].raw_affiliation_string | Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[22].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[22].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[22].institutions[0].type | nonprofit |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Stanley R Riddell |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA |
| authorships[23].author.id | https://openalex.org/A5044083912 |
| authorships[23].author.orcid | https://orcid.org/0000-0002-1407-6546 |
| authorships[23].author.display_name | Nathalie Labarrière |
| authorships[23].countries | FR |
| authorships[23].affiliations[0].raw_affiliation_string | LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| authorships[23].affiliations[1].institution_ids | https://openalex.org/I154526488 |
| authorships[23].affiliations[1].raw_affiliation_string | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France |
| authorships[23].institutions[0].id | https://openalex.org/I154526488 |
| authorships[23].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[23].institutions[0].type | government |
| authorships[23].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[23].institutions[0].country_code | FR |
| authorships[23].institutions[0].display_name | Inserm |
| authorships[23].author_position | last |
| authorships[23].raw_author_name | Nathalie Labarriere |
| authorships[23].is_corresponding | True |
| authorships[23].raw_affiliation_strings | Inserm UMR1232, CRCINA, Nantes, Pays de la Loire, France, LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11491 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | CAR-T cell therapy research |
| related_works | https://openalex.org/W2891843407, https://openalex.org/W4282962706, https://openalex.org/W3180226853, https://openalex.org/W2577091647, https://openalex.org/W3105327189, https://openalex.org/W4307641253, https://openalex.org/W1906024606, https://openalex.org/W2914185773, https://openalex.org/W1954489675, https://openalex.org/W2364115806 |
| cited_by_count | 65 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 9 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 16 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 17 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 13 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 10 |
| locations_count | 5 |
| best_oa_location.id | doi:10.1136/jitc-2020-001631 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2754803477 |
| best_oa_location.source.issn | 2051-1426 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2051-1426 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Journal for ImmunoTherapy of Cancer |
| best_oa_location.source.host_organization | https://openalex.org/P4310319945 |
| best_oa_location.source.host_organization_name | BMJ |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319945 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal for ImmunoTherapy of Cancer |
| best_oa_location.landing_page_url | https://doi.org/10.1136/jitc-2020-001631 |
| primary_location.id | doi:10.1136/jitc-2020-001631 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2754803477 |
| primary_location.source.issn | 2051-1426 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2051-1426 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Journal for ImmunoTherapy of Cancer |
| primary_location.source.host_organization | https://openalex.org/P4310319945 |
| primary_location.source.host_organization_name | BMJ |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319945 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | https://jitc.bmj.com/content/jitc/8/2/e001631.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal for ImmunoTherapy of Cancer |
| primary_location.landing_page_url | https://doi.org/10.1136/jitc-2020-001631 |
| publication_date | 2020-11-01 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W1940241680, https://openalex.org/W2049553585, https://openalex.org/W2039123767, https://openalex.org/W2281666530, https://openalex.org/W1889335134, https://openalex.org/W2010121426, https://openalex.org/W2107484016, https://openalex.org/W2057893793, https://openalex.org/W2160834915, https://openalex.org/W2254907138, https://openalex.org/W2185075416, https://openalex.org/W2164536401, https://openalex.org/W2913558101, https://openalex.org/W2907549567, https://openalex.org/W2807534769, https://openalex.org/W2435243879, https://openalex.org/W2605630275, https://openalex.org/W2916647762, https://openalex.org/W2403400382, https://openalex.org/W2769385333, https://openalex.org/W1987165863, https://openalex.org/W2225828937, https://openalex.org/W2592785733, https://openalex.org/W2737422738, https://openalex.org/W2513922839, https://openalex.org/W2506616866, https://openalex.org/W2497442705, https://openalex.org/W2501034558, https://openalex.org/W2889555301, https://openalex.org/W2909486828, https://openalex.org/W2898272383, https://openalex.org/W2890527521, https://openalex.org/W2903317594, https://openalex.org/W2609289346, https://openalex.org/W2168850569, https://openalex.org/W2107018762, https://openalex.org/W2137526110, https://openalex.org/W2146512944, https://openalex.org/W2081098333, https://openalex.org/W2142415307, https://openalex.org/W2112220625, https://openalex.org/W2010457001, https://openalex.org/W2898830231, https://openalex.org/W2790484425, https://openalex.org/W2029399624, https://openalex.org/W2592666036, https://openalex.org/W2592133876, https://openalex.org/W2801641802, https://openalex.org/W2155959680, https://openalex.org/W1980137951, https://openalex.org/W2472697448, https://openalex.org/W2849303123, https://openalex.org/W2804073610, https://openalex.org/W2573158190, https://openalex.org/W2945224722, https://openalex.org/W2950413690, https://openalex.org/W2952815301, https://openalex.org/W2951598503, https://openalex.org/W1972755885, https://openalex.org/W2894796660, https://openalex.org/W2908581980, https://openalex.org/W2966465234, https://openalex.org/W6674753063, https://openalex.org/W2239788766, https://openalex.org/W2101653483, https://openalex.org/W2886498337, https://openalex.org/W2989811984, https://openalex.org/W2971003754, https://openalex.org/W2339890238, https://openalex.org/W2761575992, https://openalex.org/W2901601525, https://openalex.org/W2888750407, https://openalex.org/W2466658396, https://openalex.org/W2902489593, https://openalex.org/W2912191040, https://openalex.org/W2887577080, https://openalex.org/W3005134677, https://openalex.org/W3007632958, https://openalex.org/W3005411249, https://openalex.org/W2889551126, https://openalex.org/W2099854994, https://openalex.org/W2560367415, https://openalex.org/W2123556891, https://openalex.org/W2111333846, https://openalex.org/W2572174216, https://openalex.org/W2171633892 |
| referenced_works_count | 86 |
| abstract_inverted_index.+ | 78, 119, 121, 124, 206, 208 |
| abstract_inverted_index.1 | 7, 127 |
| abstract_inverted_index.T | 79, 92, 156, 168 |
| abstract_inverted_index.a | 160, 175, 199 |
| abstract_inverted_index.We | 38, 88, 111 |
| abstract_inverted_index.an | 212 |
| abstract_inverted_index.as | 182, 184, 211 |
| abstract_inverted_index.at | 59 |
| abstract_inverted_index.be | 35 |
| abstract_inverted_index.in | 146 |
| abstract_inverted_index.of | 14, 48, 76, 107, 116, 129, 163, 187, 216 |
| abstract_inverted_index.on | 12, 23, 82 |
| abstract_inverted_index.to | 34, 103, 219 |
| abstract_inverted_index.we | 72 |
| abstract_inverted_index.CD8 | 77, 123, 165 |
| abstract_inverted_index.Our | 196 |
| abstract_inverted_index.and | 50, 61, 69, 84, 99, 137, 151, 155 |
| abstract_inverted_index.are | 32 |
| abstract_inverted_index.for | 179, 202 |
| abstract_inverted_index.key | 161 |
| abstract_inverted_index.the | 114, 164, 185, 192 |
| abstract_inverted_index.was | 132, 144 |
| abstract_inverted_index.yet | 33 |
| abstract_inverted_index.DPOS | 141 |
| abstract_inverted_index.PD-1 | 57, 83, 118, 205 |
| abstract_inverted_index.This | 140 |
| abstract_inverted_index.cell | 5, 26, 43, 52, 70, 93, 169 |
| abstract_inverted_index.each | 106 |
| abstract_inverted_index.flow | 67 |
| abstract_inverted_index.four | 74 |
| abstract_inverted_index.from | 3, 44 |
| abstract_inverted_index.gene | 177 |
| abstract_inverted_index.that | 113 |
| abstract_inverted_index.this | 180, 204 |
| abstract_inverted_index.well | 183 |
| abstract_inverted_index.with | 29, 56, 134, 191 |
| abstract_inverted_index.TIGIT | 85, 120, 207 |
| abstract_inverted_index.Using | 65 |
| abstract_inverted_index.after | 63, 126 |
| abstract_inverted_index.based | 22, 81 |
| abstract_inverted_index.blood | 41 |
| abstract_inverted_index.death | 6 |
| abstract_inverted_index.early | 213 |
| abstract_inverted_index.month | 128 |
| abstract_inverted_index.these | 108 |
| abstract_inverted_index.three | 45 |
| abstract_inverted_index.(DPOS) | 122 |
| abstract_inverted_index.(PD-1) | 9 |
| abstract_inverted_index.CXCR5, | 159 |
| abstract_inverted_index.Merkel | 51 |
| abstract_inverted_index.T-cell | 142, 153 |
| abstract_inverted_index.assays | 102 |
| abstract_inverted_index.cells, | 80 |
| abstract_inverted_index.highly | 147 |
| abstract_inverted_index.immune | 25 |
| abstract_inverted_index.marker | 162, 215 |
| abstract_inverted_index.relies | 11 |
| abstract_inverted_index.robust | 19 |
| abstract_inverted_index.Methods | 37 |
| abstract_inverted_index.Results | 110 |
| abstract_inverted_index.T-cells | 125 |
| abstract_inverted_index.benefit | 2 |
| abstract_inverted_index.cohorts | 47 |
| abstract_inverted_index.defined | 174 |
| abstract_inverted_index.overall | 138 |
| abstract_inverted_index.provide | 198 |
| abstract_inverted_index.results | 197 |
| abstract_inverted_index.subsets | 27, 75 |
| abstract_inverted_index.therapy | 131 |
| abstract_inverted_index.treated | 55 |
| abstract_inverted_index.Clinical | 1 |
| abstract_inverted_index.T-cells, | 149 |
| abstract_inverted_index.analysis | 98 |
| abstract_inverted_index.baseline | 60 |
| abstract_inverted_index.clinical | 135 |
| abstract_inverted_index.efficacy | 31 |
| abstract_inverted_index.emerging | 152 |
| abstract_inverted_index.enriched | 145 |
| abstract_inverted_index.isolated | 39, 73 |
| abstract_inverted_index.markers, | 21 |
| abstract_inverted_index.melanoma | 49 |
| abstract_inverted_index.pathways | 189 |
| abstract_inverted_index.patients | 54 |
| abstract_inverted_index.receptor | 8, 94 |
| abstract_inverted_index.response | 136, 218 |
| abstract_inverted_index.sorting, | 71 |
| abstract_inverted_index.specific | 176, 188 |
| abstract_inverted_index.subsets. | 109 |
| abstract_inverted_index.targeted | 96 |
| abstract_inverted_index.therapy. | 64, 221 |
| abstract_inverted_index.activated | 148 |
| abstract_inverted_index.anti-PD-1 | 130, 220 |
| abstract_inverted_index.antitumor | 16, 100 |
| abstract_inverted_index.carcinoma | 53 |
| abstract_inverted_index.cytometry | 68 |
| abstract_inverted_index.cytotoxic | 166 |
| abstract_inverted_index.frequency | 115 |
| abstract_inverted_index.immunity. | 17 |
| abstract_inverted_index.performed | 89 |
| abstract_inverted_index.profiles. | 87 |
| abstract_inverted_index.profiling | 173 |
| abstract_inverted_index.rationale | 201 |
| abstract_inverted_index.response. | 194 |
| abstract_inverted_index.signature | 178 |
| abstract_inverted_index.survival. | 139 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.associated | 28, 133, 190 |
| abstract_inverted_index.clonotypes | 154 |
| abstract_inverted_index.convincing | 200 |
| abstract_inverted_index.documented | 112 |
| abstract_inverted_index.endogenous | 15 |
| abstract_inverted_index.expression | 86 |
| abstract_inverted_index.follicular | 167 |
| abstract_inverted_index.inhibitor, | 58 |
| abstract_inverted_index.inhibitors | 10 |
| abstract_inverted_index.monitoring | 203 |
| abstract_inverted_index.peripheral | 40 |
| abstract_inverted_index.phenotypic | 90 |
| abstract_inverted_index.population | 143, 181, 210 |
| abstract_inverted_index.programmed | 4 |
| abstract_inverted_index.reactivity | 101 |
| abstract_inverted_index.thoroughly | 104 |
| abstract_inverted_index.validated. | 36 |
| abstract_inverted_index.Conclusions | 195 |
| abstract_inverted_index.circulating | 24, 117, 209 |
| abstract_inverted_index.independent | 46 |
| abstract_inverted_index.lymphocytes | 157 |
| abstract_inverted_index.mononuclear | 42 |
| abstract_inverted_index.population. | 170 |
| abstract_inverted_index.sequencing, | 95 |
| abstract_inverted_index.therapeutic | 30, 193, 217 |
| abstract_inverted_index.Nonetheless, | 18 |
| abstract_inverted_index.characterize | 105 |
| abstract_inverted_index.Additionally, | 171 |
| abstract_inverted_index.immunological | 20 |
| abstract_inverted_index.cellular-based | 214 |
| abstract_inverted_index.longitudinally | 62 |
| abstract_inverted_index.multiparameter | 66 |
| abstract_inverted_index.overexpressing | 158 |
| abstract_inverted_index.overexpression | 186 |
| abstract_inverted_index.reinvigoration | 13 |
| abstract_inverted_index.transcriptomic | 97, 172 |
| abstract_inverted_index.tumor-specific | 150 |
| abstract_inverted_index.characterization, | 91 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 99 |
| corresponding_author_ids | https://openalex.org/A5006738419, https://openalex.org/A5044083912 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 24 |
| corresponding_institution_ids | https://openalex.org/I154526488, https://openalex.org/I4210089486 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.94328662 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |